Guidant, J&J's Cordis Settle Patent Dispute Over Drug-Coated Stents

Law360, New York (February 24, 2004, 12:00 AM EST) -- Guidant Corp. has acted to decisively settle the medical device maker’s legal challenges in the lucrative market for drug-coated stents, penning yet another settlement agreement with a major competitor.

Guidant and Johnson & Johnson’s Cordis unit agreed to agree settle all outstanding litigation over patents for drug-coated stents and co-promote Cordis’ Cypher Sirolimus-eluting coronary stent, the companies said.

Last year, Guidant was forced to make a $425 million to Cordis after a court ruled that Guidant's Multi-Link Duet Coronary Stent System infringed on the so-called Palmaz...
To view the full article, register now.